CVS Caremark ordered to pay $290M after Medicare fraud scheme exposed by former Aetna whistleblower

20.08.25 22:23 Uhr

Werte in diesem Artikel
Aktien

65,80 EUR 1,71 EUR 2,67%

Indizes

PKT PKT

18.051,2 PKT 64,8 PKT 0,36%

3.345,6 PKT 0,3 PKT 0,01%

6.715,4 PKT 4,2 PKT 0,06%

A federal judge has ordered CVS Health’s pharmacy benefit manager, Caremark, to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.Sarah Behnke, a former Aetna actuary, alleged Caremark defrauded Medicare Part D by causing false drug cost reports to be submitted in 2013 and 2014.Caremark was found liable in June and Philadelphia federal court Chief Judge Mitchell Goldberg ordered the company to pay $95 million in damages, deferring final rulings on penalties.Goldberg, who was appointed by former President George W. Bush, tripled the damages on Tuesday, finding Caremark Rx, CaremarkPCS Health and CVS Caremark Part D Services should pay a total of $289.9 million in damages and penalties, according to court documents. Goldberg also imposed $4.87 million in civil penalties.ANTI-THEFT MEASURES AT CVS ARE 'WORSE FOR BUSINESS THAN ORGANIZED SHOPLIFTING,' COLUMNIST ARGUES"We are pleased that the Behnke ruling in June was in our favor as to certain issues for CVS Pharmacy and CVS Health Corporation’s liability, and disappointed the Court found against Caremark on other issues. We plan to appeal," CVS wrote in a statement to FOX Business.In 2014, Caremark was accused of manipulating how drug costs were reported, causing Aetna and SilverScript to submit false direct and indirect remuneration reports in 2013 and 2014, according to court records.The scheme, which was allegedly designed to hide profits, led to Medicare Part D being overbilled by $95 million.LOS ANGELES WILDFIRES: BIG BUSINESSES MAKE DONATIONS, OFFER SERVICES TO THOSE IMPACTED BY INFERNOSWhile Goldberg did not find "actual knowledge" of the fraud, he found reckless disregard and deliberate ignorance warranting the steep penalties, according to a memorandum.Caremark argued that the 513 false reports submitted did not justify penalties exceeding the $95 million overcharged, citing the excessive fines clause of the Eighth Amendment and the due process clause.However, Goldberg found a $95 million fraud loss was "certainly significant."Citing precedent from a State Farm insurance case in 2003, Goldberg noted due process was not violated because the ratio of penalties to actual damages was substantially lower than previous decisions, according to court documents.CVS OPENS SMALLER FORMAT STORES AS INDUSTRY SEES BIG SHIFTGoldberg also awarded post-judgment interest, which means interest began accruing on the total $289.9 million on Tuesday, and will continue to accrue until Caremark pays in full.The interest will compensate Behnke and the government until CVS pays fully, preventing the company from delaying action.It is unclear how much of the total award Behnke will receive.GET FOX BUSINESS ON THE GO BY CLICKING HEREAetna, Sarah Behnke and U.S. Attorney David Metcalf did not immediately respond to FOX Business' requests for comment.Weiter zum vollständigen Artikel bei FOX Business

In eigener Sache

Übrigens: CVS Health und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Aetna

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Aetna

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: FOX Business

Nachrichten zu CVS Health Corp

Wer­bung

Analysen zu CVS Health Corp

DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
26.10.2018CVS Health Peer PerformWolfe Research
DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
30.01.2018CVS Health Strong BuyNeedham & Company, LLC
02.01.2018CVS Health BuyNeedham & Company, LLC
DatumRatingAnalyst
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
26.10.2018CVS Health Peer PerformWolfe Research
28.06.2017CVS Health HoldNeedham & Company, LLC
02.02.2017CVS Health NeutralRobert W. Baird & Co. Incorporated
22.06.2016CVS Health HoldDeutsche Bank AG
DatumRatingAnalyst
25.07.2005Update Longs Drug Stores Corp.: UnderperformBear Stearns

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CVS Health Corp nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen